Eupraxia Pharma Announces Treatment Outcomes From Ongoing RESOLVE Phase 1b/2a Trial Evaluating EP-104GI For Treatment Of Eosinophilic Esophagitis

• At 9 months active drug continued to be released into the esophagus in patients at a rate similar to what was seen at the 3- and 6-month time points. This is an unprecedented result with an injectable delivery system in patients with EoE
• Also, at 9 months patients demonstrated sustained or improved treatment outcomes compared to 3- and 6-month results
• Additional long-term data to be released with higher doses in Q3 2025
• Eupraxia to host webinar with guest, Dr. Evan Dellon, to discuss data from RESOLVE trial on Friday, May 9th at 9:00am ET (Register here)
   

VICTORIA, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced positive treatment outcomes from its ongoing RESOLVE Phase 1b/2a trial evaluating EP-104GI for the treatment of eosinophilic esophagitis ("EoE"). Most notably, nine-month data was disclosed for the first time demonstrating that all three patients dosed at 48mg of EP-104GI experienced sustained or improved treatment outcomes after nine months of therapy.